The Latest Breaking News from Aduhelm

Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.

Washington (AFP) - The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in the early stages of Alzheimer's disease.

A Medicare policy decision might hurt sales of this biotech giant's Alzheimer's drug.

Medicare officially restricted use of Biogen's Alzheimer's treatment, Aduhelm, to patients enrolled in clinical studies.

Biogen Inc. on Wednesday published the full efficacy results from two late-stage studies of its Alzheimer’s disease drug Aduhelm in a lesser-known medical journal, nine months after U.S. regulators cleared the treatment.

Eisai Co Ltd (OTC:ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ:BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% of…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Medicare has proposed limiting coverage of Aduhelm. Key groups representing patients and families are pressing to make it more widely available. Among people facing the disease, the outlook is more nuanced.

Competing campaigns look to influence the debate over dramatically restricting coverage of a controversial treatment drug Aduhelm.